Table of Contents
ISRN Urology
Volume 2011, Article ID 392014, 5 pages
http://dx.doi.org/10.5402/2011/392014
Research Article

Assessment of the Effects of Zoledronic Acid Therapy on Bone Metabolic Indicators in Hormone-Resistant Prostate Cancer Patients with Bone Metastatasis

1Department of Urology, Erciyes University Faculty of Medicine, Kayseri, Turkey
2Department of Nuclear Medicine, Erciyes University Faculty of Medicine, Kayseri, Turkey

Received 17 February 2011; Accepted 4 April 2011

Academic Editors: P.-L. Chang and F. Staerman

Copyright © 2011 Abdullah Demirtas et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. E. Reiter and J. B. de Kernion, “Epidemiology, etiology and prevention of prostate cancer,” in Campbell’s Urology, P. C. Walsh, A. B. Retik, E. D. Vaughan Jr., and A. J. Wein, Eds., pp. 3003–3024, W. B. Saunders, Philadelphia, Pa, USA, 8th edition, 2002. View at Google Scholar
  2. K. A. Harris and D. M. Reese, “Treatment options in hormone-refractory prostate cancer: current and future approaches,” Drugs, vol. 61, no. 15, pp. 2177–2192, 2001. View at Google Scholar · View at Scopus
  3. E. T. Keller, J. Zhang, C. R. Cooper et al., “Prostate carcinoma skeletal metastases: cross-talk between tumor and bone,” Cancer and Metastasis Reviews, vol. 20, no. 3-4, pp. 333–349, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. R. E. Coleman, “Bisphosphonates: clinical experience,” Oncologist, vol. 9, no. 4, pp. 14–27, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. H. Fleisch, “Development of bisphosphonates,” Breast Cancer Research, vol. 4, no. 1, pp. 30–34, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. C. L. Eaton and R. E. Coleman, “Pathophysiology of bone metastases from prostate cancer and the role of biphosphonates in treatment,” Cancer Treatment Reviews, vol. 29, no. 3, pp. 189–198, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. C. De la Piedra, N. A. Castro-Errecaborde, M. L. Traba et al., “Bone remodeling markers in the detection of bone metastases in prostate cancer,” Clinica Chimica Acta, vol. 331, no. 1-2, pp. 45–53, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Garnero, N. Buchs, J. Zekri, R. Rizzoli, R. E. Coleman, and P. D. Delmas, “Markers of bone turnover for the management of patients with bone metastases from prostate cancer,” British Journal of Cancer, vol. 82, no. 4, pp. 858–864, 2000. View at Google Scholar · View at Scopus
  9. R. Weston, S. A. Hussain, R. N. Stephenson et al., “Changes in bone mineral density in patients receiving hormonal manipulation and testosterone recovery following cessation of long term LH-RH analogues,” in Proceedings of the British Association of Urological Surgeons Annual Meeting, Manchester, UK, 2003.
  10. H. W. Daniell, “Osteoporosis after orchiectomy for prostate cancer,” Journal of Urology, vol. 157, no. 2, pp. 439–444, 1997. View at Publisher · View at Google Scholar · View at Scopus
  11. S. A. Hussain, R. Weston, R. N. Stephenson, E. George, and N. J. Parr, “Immediate dual energy X-ray absorptiometry reveals a high incidence of osteoporosis in patients with advanced prostate cancer before hormonal manipulation,” British Journal of Urology International, vol. 92, no. 7, pp. 690–694, 2003. View at Publisher · View at Google Scholar
  12. F. Saad, D. M. Gleason, R. Murray et al., “A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma,” Journal of the National Cancer Institute, vol. 94, no. 19, pp. 1458–1468, 2002. View at Google Scholar
  13. J. R. Berenson, “Recommendations for zoledronic acid treatment of patients with bone metastases,” Oncologist, vol. 10, no. 1, pp. 52–62, 2005. View at Publisher · View at Google Scholar · View at PubMed
  14. R. E. Coleman, “Monitoring of bone metastases,” European Journal of Cancer, vol. 34, no. 2, pp. 252–259, 1998. View at Publisher · View at Google Scholar
  15. J. Schoenberger, S. Rozeboom, E. Wirthgen-Beyer, and C. Eilles, “Evaluation of the clinical value of bone metabolic parameters for the screening of osseous metastases compared to bone scintigraphy,” BMC Nuclear Medicine, vol. 4, no. 3, pp. 1–9, 2004. View at Publisher · View at Google Scholar · View at PubMed
  16. P. Garnero, E. Sornay-Rendu, M. C. Chapuy, and P. D. Delmas, “Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis,” Journal of Bone and Mineral Research, vol. 11, no. 3, pp. 337–349, 1996. View at Google Scholar
  17. P. R. Carrol, J. Altwein, O. Brawley et al., “Management of disseminated prostate cancer,” The American Journal of Urology Review, vol. 171, pp. 39–40, 2004. View at Google Scholar
  18. S. Mercadante, “Malignant bone pain: pathophysiology and treatment,” Pain, vol. 69, no. 1-2, pp. 1–18, 1997. View at Publisher · View at Google Scholar
  19. R. Wong and P. J. Wiffen, “Bisphosphonates for the relief of pain secondary to bone metastases,” Cochrane database of systematic reviews (Online), no. 2, article CD002068, 2002. View at Google Scholar